



Alaska Medical Assistance DUR Committee Meeting  
Friday, January 22<sup>nd</sup>, 2016  
1:00pm  
1.800.315.6338, access code 24251#

## Agenda

- (1) Review of minutes from the last meeting
- (2) Review of agenda
- (3) Comments/Suggestions from Committee members
- (4) Prospective Drug Utilization Review / Clinical Topic Areas:
  - a. New Prescription Medications (Interim PA List – 6 month review)
    1. Butrans
  - b. Review of existing Prior Authorizations, Quantity Limits, Edits
    - i. FDA Indication Changes
      1. Xifaxan
    - ii. FDA Label Changes
      1. Botulinum Toxin
    - iii. Periodic Review
      1. Hepatitis C Direct Acting Agents
  - c. Proposed New Prior Authorizations, Quantity Limits, Edits
    1. Naloxone Opioid Overdose Treatments
    2. Cosentyx
    3. Movantik
    4. Long Acting Atypical Antipsychotics
    5. PCSK9 Inhibitors

<<Break>>

- (5) Past Intervention Informational Updates
- (6) FDA/DEA Updates
  - a. FDA Drug Safety Communications
    - i. SGLT2 Inhibitors [12/4/2015]
    - ii. Rosiglitazone REMS Elimination [12/16/2015]
    - iii. TBD
- (7) FAERS Report
- (8) Quality Measures
- (9) Retrospective Review
  - a. Opioid Utilization
- (10) Standing Reviews
- (11) End of Public Meeting